Vetcontact
Bayer Novartis Boehringer-Ingelheim Virbac France
Vetcontact Events Presentations Posters Case Studies Speciality Organisations
CPD Forum Products Login/Newsletter
Oncology Home ONCOLOGY
NEW FDA REPORT ON ACRYLAMIDE
Acrylamide is a cancerogenic substance at least in laboratory animals. A lot is written and discussed about its creation, e.g. when french fries are made under high temperatures. But this substance can also be found in food additives, and so the FDA released a report concerning acrylamide some days ago.

The Food and Drug Administration (FDA) is reviewing a report released on March 2, from the Food and Agriculture Organization and World Health Organization Joint Expert Committee on Food Additives (JECFA) on acrylamide in food.

Acrylamide is a natural byproduct that forms when certain carbohydrate-rich foods are fried, baked, or roasted at high temperatures. Acrylamide can cause cancer in laboratory animals at high doses, although it is not clear whether it causes cancer at the much lower levels in food.

`FDA has been at the forefront of developing the science needed to fully assess acrylamide,` said Dr. Robert Brackett, FDA`s Director of the Center for Food Safety and Applied Nutrition. `We look forward to thoroughly assessing JECFA`s latest findings on this issue, so that we can work together using sound science to assure the safety of our food supply.`

Since the discovery of acrylamide in food in 2002, FDA has initiated a broad range of activities on acrylamide, including being at the forefront of new toxicology research on acrylamide.

This FDA research includes the carcinogenicity and neurotoxicity studies and the toxicology modeling work cited in the JECFA recommendations. The results of these studies, expected in 2007, will be pivotal for future evaluations of acrylamide.

Experts from FDA participated in the meeting and recent FDA research on acrylamide levels in food and acrylamide toxicology were used for JECFA`s evaluation. Although the report concludes that acrylamide may be a human health concern, JECFA also cautions that there are uncertainties in its conclusions because of limitations in the data used to evaluate acrylamide. JECFA also made the following recommendations that are consistent with the FDA`s approach:

Reevaluate acrylamide when ongoing carcinogenicity and long-term neurotoxicity studies are available;
Continue work on acrylamide using toxicology modeling;
Continue appropriate efforts to reduce acrylamide concentrations in food; and
Encourage accumulation of scientific data on acrylamide in foods in developing countries.


At this time, FDA advises consumers to eat a balanced diet, choosing a variety of foods that are low in trans fat and saturated fat, and rich in high-fiber grains, fruits, and vegetables. FDA is also planning to release new data this spring on acrylamide levels in the U.S. diet.

Source http://www.cfsan.fda.gov/~lrd/pestadd.html#acrylamide.





Tell a friend   |   Print version   |   Send this article

Toceranib phosphate (Palladia®) in canine gastrointestinal stromal tumors Gastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. Literature regarding adjunctive therapy for GISTs in dogs is sparse. Highâ€risk GISTs in humans respond to tyrosine kinase inhibition in the adjuvant setting. This recently online published study reviews cases of toceranib phosphate use in dogs with GISTs and provides initial assessment of possible biological activity. A secondary aim was to evaluate patient and tumor characteristics for possible prognostic value.

  • Hypoechoic tissue changes in dogs with malignant prostatic lymphoma
  • Novel intratumoral therapy in canine transmissible venereal tumour
  • ACVIM small animal consensus statement on safe use of cytotoxic chemotherapeutics
  • Extracellular vesicles in mammary cancer of dogs and cats
  • Non-tuberculous Mycobacteria in healthy slaughtered cattle and the abattoir
  • Canine mammary tumours as model for hereditary breast cancer susceptibility genes in humans
  • Malignant anal sac melanoma in dogs
  • Carboplatin sustained-release delivery system in dogs with cancer
  • Novel radiation therapy for inoperable massive hepatocellular carcinoma
  • Red blood cell storage lesion - an update
  • Canine osteosarcoma cells and aurora kinase inhibitors
  • Exocrine pancreatic neoplasias in cats - the most common signs
  • Radiation therapy of oral melanomas in cats
  • Successful treatment of persistent oral papillomatosis with a recombinant oral vaccine
  • Photodynamic therapy in equine periocular squamous cell carcinoma
  • Masitinib in canine mast cell tumors
  • Latent viral phase in horses with sarcoids?
  • Calcified tumours of the paranasal sinuses in horses
  • Canine cerebellar leptomeningeal carcinomatosis (case report)
  • Canine Cutaneous Perivascular Wall Tumors
  • Reconstruction of the lower eyelid in cats with squamous cell carcinoma
  • Transposition of first digital pad for reconstruction of a soft tissue defect (case report)
  • Connexins 26 and 43 in canine hyperplastic and neoplastic mammary glands
  • Advances in mast cell tumour diagnosis and therapy
  • Survival time in dogs with non-treated nasal carcinomas
  • Paraneoplastic alopecia associated with liver carcinoma in a cat (case report)
  • Are mast cell tumors in the groin or perineal region more aggressive than elsewhere?
  • Mitotic index and the survival time in canine cutaneous mast cell tumors
  • Stromal tumors in the gastrointestinal tract of equids
  • Osteosarcoma in horses
  • Maropitant in the treatment of cisplatin-induced emesis in dogs
  • Reevaluation of the 2-Year Protocol for Treating Canine Lymphosarcoma
  • Malignant ameloblastic fibro-odontoma in a Collie (case report)
  • Epithelioid variant of hemangioma and hemangiosarcoma in various species
  • New canine osteosarcoma cell line
  • Chemotherapy plus half-body radiation therapy for canine lymphoma
  • Recurrence rate of surgically excised grade II mast cell-tumors
  • Intestinal T-cell lymphoma in dogs
  • Prognostic factors in multiple cutaneous mast cell tumours
  • Bilateral salivary adenocarcinoma with multiple metastases in a cat
  • Lineage differentiation of canine lymphoma/leukemias
  • Partial esophagectomy in esophageal sarcomas in dogs
  • Surgery alone or surgery plus chemotherapy in feline injection-site lymphosarcomas?
  • Biphasic synovial sarcoma in a young dog: pathologic features
  • Canine Hemophagocytic Histiocytic Sarcoma
  • Cutaneous and mucocutaneous plasmacytomas in dogs
  • Mast cells and angiogenesis in canine melanomas - prognostic factors
  • No higher incidence of diseases in rescue dogs from September 9th
  • Conjunctival hemangioma and hemangiosarcoma in the dog
  • Uveal metastasis of a primary pulmonary adenocarcinoma
  • Vascular hamartoma in a horse
  • Correlation of CT-MRI and histopathology in dogs with brain neoplasms
  • Indolent Nodular Lymphoma in Dogs
  • Pugs and mast cell tumours
  • Cerebellar myxoid type meningioma in a dog
  • Carboplatin in canine tonsillar squamous cell carcinoma
  • Partial foot amputation in dogs
  • Mast cells and angiogenesis in canine melanomas
  • Immunhistochemistry in canine unidentified round cell tumors
  • First gastric carcinoid in a cat
  • Thyroid carcinoma in dogs - is surgical resection sufficient?
  • Vaccine-induced rhabdomyosarcoma in a cat
  • Gastric adenocarcinomas and leiomyosarcomas
  • Colorectal plasmocytomas - how do they behave?
  • ACTH tests in dogs with different neoplasia
  • Collie eye anomaly in a non-Collie breed
  • How does the immune system recognize and respond to cancer?
  • Gemcitabine as radiosensitizer for nonresectable oral SCC in cats
  • Multicentric intravascular lymphoma in the nervous system of a dog (case report)
  • Ectopic secretion of GHRH
  • MRI in the differentiation between neoplastic and non-neoplastic brain lesions
  • Acromegaly in cats
  • Glioblastoma multiforme in dogs
  • Malignant craniopharyngioma in two cats: histopathological findings
  • Skin myxoma in a dog (case report)
  • Acute granulocytic ehrlichiosis in a dog (case report)
  • Skin metastases of a bronchial adenocarcinoma in a cat (case report)
  • Osteosarcoma 11 years after TPO
  • Malignant B-cell lymphoma of the Harder`s gland in a rabbit (case report)
  • Mixed pancreatic acinar-endocrine carcinoma in a dog (case report)
  • Successful stem-cell transplantation in a dog with cancer
  • Carboplatin and piroxicam in transitional cell carcinoma of the bladder
  • Hypercalcemia caused by oral neoplasia
  • One or two doses of cisplatin in canine osteosarcoma?
  • Monoclonal gammopathies in dogs: the most common reasons
  • Ureteral obstruction due to mast cell tumor
  • Intestinal Mucinous Adenocarcinoma in a Dog (case report)
  • Heat shock proteins expression in canine skin tumors
  • Piroxicam and carboplatin in canine oral non-tonsillar squamous cell carcinoma
  • Hepatobiliary neuroendocrine carcinoma in cats
  • Colorado State University receives 1 million dollars for cancer biology program
  • Total Skin Electron Beam Irradiation In Canine Mykosis Fungoides
  • Cancer is the leading cause of death in dogs and cats
  • Do eczema drugs increase the risk of cancer?
  • Piroxicam in transitional cell carcinoma of the canine bladder
  • Retrobulbar malignant fibrous histiocytoma in a dog
  • Surgical therapy of scapular osteosarcomas
  • Cox-2-expression in canine keratinocytes
  • Surgical therapy in cats with middle ear tumours with brainstem extension
  • Partial or complete foot amputation in dogs?
  • Four Fraction Palliative Radiotherapy for Canine Osteosarcoma
  • No health problems in search and rescue dogs from September 11,2001
  • Emphysematous prostatitis in a dog
  • Telomerase-targeted therapies in canine cancer cell lines
  • Promising therapy of canine haemangiosarcoma with suberoylanilide hydroxamic acid
  • The pre-surgical work-up of tumor patients
  • Sonographic characteristics of abdominal histiocytic neoplasms in dogs
  • Non-coherent light - a good alternative in treatment of superficial tumours?
  • Prednisolone plus radiotherapy for canine mast cell tumours
  • Intercalary Bone Grafts for Joint and Limb Preservation in dogs with malignant bone tumors
  • Is radiotherapy in cutaneous grade II mast cell tumors mandatory?
  • Chronic recurrent cystitis or transitional cell carcinoma - the differentiation
  • Conjunctival B-cell lymphoma in a cat
  • Intravascular lymphoma in a dog (case report)
  • Primary intratracheal lymphosarcoma in cats
  • Iridium brachytherapy plus surgery in canine mast cell tumors
  • Pancreatic adenocarcinomas in cats
  • Carmustine instead of cyclophosphamide in canine lymphoma
  • Transitional cell carcinoma in dogs - update in diagnosis and therapy
  • Pericardial effusion - cave lymphosarcoma



  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved